4.7 Article

Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials

期刊

JOURNAL OF AFFECTIVE DISORDERS
卷 150, 期 2, 页码 408-414

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jad.2013.04.032

关键词

Bipolar disorders; Mania; Mixed episodes; Second generation antipsychotics; Randomized controlled trials; Meta-analysis

资金

  1. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil
  2. Canadian Institutes of Health Research (CIHR)
  3. UBC Institute of Mental Health/Coast Capital Depression Research Fund
  4. Canadian Network for Mood and Anxiety Treatments (CANMAT)
  5. Canadian Psychiatric Association
  6. Pfizer
  7. AstraZeneca
  8. Janssen-Ortho
  9. Bristol-Myers Squibb
  10. Otsuka
  11. Biovail
  12. Canadian Psychiatric Association Foundation
  13. Eli LillyCo.
  14. Litebook Company
  15. Lundbeck, Lundbeck Institute
  16. Mochida
  17. Servier
  18. St. Jude's Medical
  19. Takeda
  20. UBC Institute of Mental Health/Coast Capital Savings
  21. Forest
  22. Janssen
  23. Michael Smith Foundation for Health Research
  24. Novartis
  25. Ranbaxy
  26. Stanley Foundation

向作者/读者索取更多资源

Background: The literature on the treatment mixed episodes in Bipolar Disorder [BD] is sparse. Second generation antipsychotics [SCA] have documented efficacy in mania, but not mixed episodes. The objective of this meta-analysis was to ascertain the efficacy of SGA, either as mono- and/or adjunctive therapy, in the treatment of acute mixed episodes of BD, compared to placebo. Methods: A MEDLINE search for English language publications of randomized controlled trials [RCTs] comparing SGA with placebo in the treatment of an acute manic/mixed episode of BD, during the period 1990-2012, was performed using the terms 'atypical antipsychotics', 'SGA', 'mixed episodes mania' and each SGA independently. 9 RCTs reporting data on 1289 mixed episode patients treated with aripiprazole, asenapine, olanzapine, paliperidone-ER, risperidone, and ziprasidone, either as monotherapy or as adjunctive therapy, versus placebo, for 3-6 weeks, were included in the meta-analysis. We extracted data on the number of patients, SGA, duration of study and mean change in mania and depression scores from baseline to endpoint. Standardized mean difference between SGA and placebo for the mean baseline-to-endpoint change in mania and depression rating scores was calculated, with a 95% confidence limit. Results: SGA, either alone or in combination with mood stabilizers, had superior efficacy in treating manic symptoms of mixed episodes compared to placebo (-0.41, 95% CI -0.53, -0.30; overall effect p < 0.00001). SCA were equally effective for manic symptoms in mixed episodes and pure mania (p=0.99). SCA had superior efficacy in treating depressive symptoms of mixed episodes (-0.30, 95% CI -0.47, -0.13; p < 0.001) compared to placebo in two trials reporting this information. Limitations: Thirteen relevant studies could not be included as data for mixed episodes were not presented separately. Conclusions: SGA are effective in treating acute mixed episodes of BD, with predominant manic symptoms. Their efficacy in treating depressed mixed episodes remains unclear. (C) 2013 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据